Cover Image
市場調查報告書

原發惡化型多發性硬化症:開發平台分析

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251571
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
原發惡化型多發性硬化症:開發平台分析 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 97 Pages
簡介

原發惡化型多發性硬化症特微是明顯的復發及無法康復,神經功能確實地持續惡化。症狀有語言及吞嚥障礙、視覺障礙、疲勞感、疼痛、排尿·排便障礙等。

本報告提供原發惡化型多發性硬化症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

原發惡化型多發性硬化症 (PPMS) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • AB Science SA
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • kyorin製藥
  • MedDay
  • Santhera Pharmaceuticals Holding AG
  • Teva Pharmaceutical Industries Limited

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ApE
  • biotin
  • GZ-402668
  • ibudilast
  • idebenone
  • laquinimod sodium
  • masitinib
  • ocrelizumab
  • 中樞神經系統障礙幹細胞療法

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8403IDB

Summary

Global Markets Direct's, 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H2 2016', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
  • The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
  • The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Progressive Multiple Sclerosis (PPMS) Overview
  • Therapeutics Development
    • Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview
  • Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies
  • Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • Glialogix, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • MedDay SA
    • Santhera Pharmaceuticals Holding AG
    • Teva Pharmaceutical Industries Ltd.
  • Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • biotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLX-1112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-402668 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-MS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • idebenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • laquinimod sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects
  • Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products
  • Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
      • Jun 28, 2016: Roche's marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
      • May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial
      • Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN
      • Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis
      • Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
      • Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003
      • Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis
      • Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS
      • Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
      • Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting
      • Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay SA, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H2 2016
  • Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top